{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Cholangiocarcinoma&page=2", "query": { "condition": "Locally Advanced Cholangiocarcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Cholangiocarcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T04:18:59.609Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06855225", "title": "A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Combined Hepatocellular and Cholangiocarcinoma" ], "interventions": [ { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mehmet Akce", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2026-05", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-10T04:18:59.609Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06855225" }, { "nct_id": "NCT00478140", "title": "Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Extrahepatic Bile Duct", "Adenocarcinoma of the Gallbladder", "Malignant Neoplasm", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2007-05", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-06-10T04:18:59.609Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00478140" }, { "nct_id": "NCT03821233", "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-expressing Cancers" ], "interventions": [ { "name": "ZW49", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zymeworks BC Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2019-04-15", "completion_date": "2024-10-08", "has_results": false, "last_update_posted_date": "2025-01-29", "last_synced_at": "2026-06-10T04:18:59.609Z", "location_count": 8, "location_summary": "Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03821233" }, { "nct_id": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Colorectal Neoplasms", "Melanoma", "Pancreatic Neoplasms", "Sarcoma", "Ovarian Neoplasms", "Brain Neoplasms", "Thyroid Neoplasms", "Neuroendocrine Tumors", "Cholangiocarcinoma", "Salivary Gland Neoplasms", "Head and Neck Neoplasms", "Thyroid Cancer, Papillary", "Lymphoma, Large-Cell, Anaplastic", "Neoplasms by Site", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasms", "Digestive System Diseases", "Gastrointestinal Diseases", "Colonic Diseases", "Intestinal Diseases", "Central Nervous System" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-05-24", "completion_date": "2022-05-16", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-06-10T04:18:59.609Z", "location_count": 29, "location_summary": "Culver City, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644315" }, { "nct_id": "NCT04068194", "title": "Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Unresectable Cholangiocarcinoma", "Locally Advanced Unresectable Gallbladder Carcinoma", "Locally Advanced Unresectable Malignant Solid Neoplasm", "Metastatic Cholangiocarcinoma", "Metastatic Gallbladder Carcinoma", "Metastatic Malignant Solid Neoplasm", "Stage III Gallbladder Cancer AJCC v8", "Stage IV Gallbladder Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Peposertib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2020-04-07", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-10T04:18:59.609Z", "location_count": 46, "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 34 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068194" }, { "nct_id": "NCT05655949", "title": "Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bile Duct Cancer", "Cholangiocarcinoma", "Cholangiocarcinoma Non-resectable", "Cholangiocarcinoma Metastatic", "Metastatic Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Yttrium-90", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-13", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-06-10T04:18:59.609Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05655949" }, { "nct_id": "NCT04666688", "title": "LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Solid Tumor", "Pancreatic Cancer", "Urothelial Carcinoma", "Head and Neck Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LYT-200", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Gemcitabine/nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PureTech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2020-12-15", "completion_date": "2024-12-12", "has_results": false, "last_update_posted_date": "2025-02-12", "last_synced_at": "2026-06-10T04:18:59.609Z", "location_count": 12, "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666688" }, { "nct_id": "NCT04641871", "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "Sym021", "type": "DRUG" }, { "name": "Sym022", "type": "DRUG" }, { "name": "Sym023", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2020-10-12", "completion_date": "2024-06-03", "has_results": false, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-06-10T04:18:59.609Z", "location_count": 12, "location_summary": "Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04641871" }, { "nct_id": "NCT02568267", "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Cholangiocarcinoma", "Colorectal Cancer", "Head and Neck Neoplasms", "Lymphoma, Large-Cell, Anaplastic", "Melanoma", "Neuroendocrine Tumors", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Papillary Thyroid Cancer", "Primary Brain Tumors", "Renal Cell Carcinoma", "Sarcomas", "Salivary Gland Cancers", "Adult Solid Tumor" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 534, "start_date": "2015-11-19", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-06-10T04:18:59.609Z", "location_count": 53, "location_summary": "Phoenix, Arizona • Duarte, California • La Jolla, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02568267" }, { "nct_id": "NCT06178588", "title": "Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Cholangiocarcinoma", "Metastatic Cholangiocarcinoma", "Recurrent Cholangiocarcinoma", "Stage III Hilar Cholangiocarcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Hilar Cholangiocarcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2024-02-01", "completion_date": "2026-11-01", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-06-10T04:18:59.609Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06178588" } ] }